Treating Tardive Dyskinesia: Clinical Challenges and Patient Perspectives
|
|
- Arline Greene
- 5 years ago
- Views:
Transcription
1 Treating Tardive Dyskinesia: Clinical Challenges and Patient Perspectives Interim Outcomes Report (as of November 20, 2018) Supported by an educational grant from Neurocrine Biosciences
2 Overview Activity Description: This HD video roundtable discussion includes two leading expert psychiatrists, who participate in a panel discussion of tardive dyskinesia (TD) as a widespread and undertreated condition in psychiatric populations, as well as the importance of evidence-based differential diagnostics, newly approved therapeutics for treatment of the condition, and strategies for both personalized and improved patient care. This activity also includes an interview with a leading neurologist who reviews diagnostic algorithms for TD and shares her perspective on the impact of new drug approvals and strategies for working together with psychiatrists in managing patients with TD. Throughout the activity, testimonials of a patient with tardive dyskinesia are incorporated to bring relevance to the patient perspective, experience and treatment goals. Launch Date: August 31, 2018 Expiration Date: August 31, 2019 Credit: 1.00 AMA PRA Category 1 Credit(s) TM Sponsored by: The Academy for Continued Healthcare Learning (ACHL) Supported by: An educational grant from Neurocrine Biosciences Intended Audience: This activity is intended for psychiatrists, neurologists, and other clinicians involved in the management of patients with TD. Outcomes Methodology: Activity-related changes in clinician knowledge, competence, and practices were evaluated using Level 5 outcomes to determine whether the educational objectives of the activity were achieved. Activity Availability:
3 Activity Screenshots
4 Executive Summary Participation (as of November 20, 2018) 2068 Clinical Participants; 552 Certificates (exceeds guarantee of 1500 participants!) Practicing Type Physicians, 31% Physician Assistant, 18% NP/RNs, 2% Pharmacist, 9% Other HCP Participant Satisfaction Objectivity and balance rated as good/excellent by 98% of learners Learning Objectives 99% of learners strongly agree or agree that all learning objectives were met, with an average rating of 3.43/4.0 Faculty All faculty were highly rated 3.61/4.0
5 Executive Summary (Cont d) 49% indicated participation in the activity will impact their patient outcomes. 54% of participants identified that they will change their practice by increasing evaluation of their patients for physical symptoms and/or manifestations of TD. Changes made from this activity will impact 1,389 to more than 2,711 TD patients each month. Lack of experience, lack of opportunity (patients) and reimbursement/insurance issues were reported as the most common barriers to implementing changes in practice. Following the activity, learners demonstrated increased knowledge of the causes of TD as well as the treatment efficacy of valbenazine/deutetrabenazine in their respective clinical trials.
6 Level 1: Participation Participants Certificates Participation by Specialty Participation by Clinician Type Physician Physician Assistant 2% 9% Nurse Practitioner 6% Nurse Pharmacist 12% Other HCP Family Medicine/General Practice Psychiatry Pain Medicine Internal Medicine Emergency Medicine 16% Surgery Neurology 4% Orthopedics Other 8% 6% 18% 31% 4% 5% 2% 37%
7 Level 2: Learning Objectives Please rate the following objectives to indicate if you are better able to: Evaluate possible clinical indication(s) and patient population(s) that may be at increased risk for tardive dyskinesia (TD) Discuss the role of dopamine antagonists and/or other therapies that may play a role in the pathophysiology of TD Recognize the risks, benefits, and possible complications associated with managing TD in the psychiatric population Describe the importance of differential diagnosis and current evidence-based treatment paradigms for patients at risk for TD Interpret the clinical trial efficacy and safety data of novel and emerging therapies for TD Analysis of Respondents Rating scale: 4=Strongly Agree; 1=Strongly Disagree % of learners strongly agree or agree that all learning objectives were met, with an average rating of N=542
8 Level 2: Faculty & Overall Evaluation Please rate the faculty on the criterion listed Analysis of Respondents The faculty were rated good or excellent by 99% of learners Rating scale: 4=Excellent; 1=Poor Expertise on the subject matter 3.61 Overall Evaluation Analysis of Respondents Rating scale: 4=Excellent; 1=Poor Quality of educational content 3.58 Scientific rigor 3.54 N=541
9 Level 2: Objectivity & Balance Did you perceive any bias? Rating of objectivity & balance 1% 55% 43% 99% 2% Excellent Good Fair Poor Yes No N=542 Activity was perceived as objective, balanced and non-biased.
10 Levels 3-4: Planned Frequency During a consultation, how likely are you to evaluate your patient for the physical symptoms and/or manifestations of tardive dyskinesia? If a patient is suspected of having TD, how likely are you to undertake differential diagnosis of the patient for TD? % 28% Definitely likely Pre (n=665) 38% 32% Very likely Post (n=542) 25% 19% Somewhat likely 15% 8% Not at al likely % 28% Definitely likely Pre (n=665) 41% Very likely Post (n=542) 25% 19% Somewhat likely 7% 5% Not at al likely Following the activity, 73% of learners indicated a high likelihood of evaluating patients for the physical symptoms and/or manifestations of TD vs of learners prior to the activity. Following participation in this activity, 76% of learners are highly likely to undertake a differential diagnosis of their patients for TD compared to 68% of learners prior to the activity.
11 Pretest vs. Posttest Summary Overview of Correct Responses Pre Post Topic % Change Topic 1: Recognizing Causes of TD 76% 51% 9 84% 85% 62% 95% Topic 2: Deutetrabenazine in the AIM- TD Trial 163% 32% 37% Topic 3: Valbenazine in the KINECT-3 Trial for TD 13 Topic 4: TD Patient Case for Treatment 52% Topic 1 Topic 2 Topic 3 Topic 4 Participants demonstrated improved knowledge and competence on four of four pre/posttest questions.
12 Levels 3-5: Pretest vs. Posttest vs. Follow-up Recognizing Causes of TD Pre (n=665) Post (n=550) Follow-up (n=7) 1. The following statements about the development of TD is correct EXCEPT: A. Neuroleptic-induced D2 receptor hypersensitivity in the nigrostriatal pathway is one of the suspected underlying causes B. Patients stop experiencing the pathology after dopamine antagonist therapy is terminated C. D2 receptor hypersensitivity may be at least partially due to a genetic variant D. Dopamine signaling results in the involuntary movements characteristic of the disorder % 57% 29% 24% 12% 13% 14% 4% 3% 3% Following the educational activity, there was a 76% increase in knowledge and awareness of the causes of TD, particularly that patients do not stop experiencing TD after dopamine antagonist therapy is terminated. This recognition is critical for clinicians to properly and accurately assess patients susceptible to TD and, following diagnosis, prescribe treatment. Additional educational reinforcement may be warranted in this topic as participants retention in the follow-up survey slipped 30 days post activity. For the final outcomes report, follow-up questions will solicit additional demographic data from responders in order to isolate target audience performance.
13 Pretest vs. Posttest Response by Specialty 1. The following statements about the development of TD is correct EXCEPT: Pre (n=228) Post (n=185) Pre (n=45) Post (n=37) Pre (n=391) Post (n=327) 89% 66% 84% 91% 18% 4% 8% 3% 8% 4% Psychiatrists 56% 18% 1 11% 15% 3% 3% Neurologists 42% 27% 15% 16% 3% 3% 3% Other HCPs Following the educational activity, there was a marked increase in knowledge and awareness of the causes of TD, particularly that patients do not stop experiencing TD after dopamine antagonist therapy is terminated. Psychiatrists demonstrated a 35% increase, neurologists a 5 increase and other HCPs the highest level at 117%. Such increases in recognition are critical for clinicians to properly and accurately assess patients susceptible to TD and, following diagnosis, prescribe treatment.
14 Levels 3-4: Pretest vs. Posttest Deutetrabenazine in the AIM-TD Trial Pre (n=665) Post (n=550) 2. The double-blind, randomized, phase 3, placebo-controlled AIM-TD trial evaluated the effect of 3 doses of deutetrabenazine (12 mg/day, 24 mg/day, and 36 mg/day) on the change in AIMS score from baseline to week 12. In the AIM-TD trial, which doses of deutetrabenazine were found to statistically reduce the AIMS score, compared with placebo? A. Only the 12 mg/day and 24 mg/day doses of deutetrabenazine statistically reduced the AIMS score, compared with placebo B. Only the 24 mg/day and 36 mg/day doses of deutetrabenazine statistically reduced the AIMS score, compared with placebo C. All 3 doses of deutetrabenazine statistically reduced the AIMS score, compared with placebo D. None of the doses of deutetrabenazine statistically reduced the AIMS score, compared with placebo % 39% 32% 22% 13% 7% 2% 1% Following the educational activity, knowledge and awareness of the effective doses of deutetrabenazine used in the AIM-TD clinical trial to improve patient outcomes increased by a dramatic 163% in participants. Evaluating and understanding the effective doses of deutetrabenazine is important for appropriate and effective clinical utilization of these newly approved agents.
15 Pretest vs. Posttest Response by Specialty 2. The double-blind, randomized, phase 3, placebo-controlled AIM-TD trial evaluated the effect of 3 doses of deutetrabenazine (12 mg/day, 24 mg/day, and 36 mg/day) on the change in AIMS score from baseline to week 12. In the AIM-TD trial, which doses of deutetrabenazine were found to statistically reduce the AIMS score, compared with placebo? Pre (n=228) Post (n=185) Pre (n=45) Post (n=37) Pre (n=389) 9 Post (n=327) 75% 76% 48% 28% 16% 21% 3% 8% 1% 36% 44% 16% 22% 2% 4% 26% 33% 33% 2% 7% 8% 1% Psychiatrists Neurologists Other HCPs Following the educational activity, knowledge and awareness of the effective doses of deutetrabenazine used in the AIM-TD clinical trial to improve patient outcomes increased dramaticly in participants. Psychiatrists demonstrated an impressive 168% increase, neurologists an 111% increase and other HCPs the highest level at 172%. Evaluating and understanding the effective doses of deutetrabenazine is important for appropriate and effective clinical utilization of these newly approved agents.
16 Levels 3-4: Pretest vs. Posttest Valbenazine in the KINECT-3 Trial for TD Pre (n=665) Post (n=550) 3. Recent clinical data from the phase 3 KINECT-3 trial for TD demonstrated the following: A. At week 6 in the intent-to-treat population, treatment with valbenazine at 80 mg/day resulted in a significant reduction in AIMS dyskinesia score compared with placebo B. Differences in AIMS dyskinesia score change from baseline were evident only in the 80 mg/day valbenazine treatment group, but not the 40 mg group, compared with placebo at visits on weeks 2, 4 and 6 in the intentto-treat population C. An equal percentage of participants receiving 80 mg/day valbenazine or placebo had a 5 improvement in their AIMS dyskinesia score at visits on weeks 2, 4 and 6 D. AIMS dyskinesia score improvement at week 6 in the intent-to-treat population was associated with suicidal ideation as an adverse event % 37% 3 21% 8% 5% 12% 2% Following the educational activity, learners demonstrated a dramatic increase of 13 in knowledge and awareness of the primary outcome of the KINECT-3 trial of valbenazine to reduce the AIMS dyskinesia score in trial patients. Understanding the practice-changing outcome of such a pivotal trial is crucial for widespread and effective clinical utilization of valbenazine as a newly approved agent.
17 Pretest vs. Posttest Response by Specialty 3. Recent clinical data from the phase 3 KINECT-3 trial for TD demonstrated the following: Pre (n=228) 87% Post (n=185) Pre (n=45) 87% Post (n=37) Pre (n=391) 84% Post (n=327) 43% 29% 5% 7% 8% 1% 44% 27% 18% 8% 11% 5% 36% 3 22% 1 12% 4% 2% Psychiatrists Neurologists Other HCPs Following the educational activity, learners demonstrated great increases in knowledge and awareness of the primary outcome of the KINECT-3 trial of valbenazine to reduce the AIMS dyskinesia score in trial patients. Psychiatrists demonstrated a 102% increase, neurologists the highest at a 202% increase and other HCPs at 133%. Understanding the practice-changing outcome of such a pivotal trial is crucial for widespread and effective clinical utilization of valbenazine as a newly approved agent.
18 Levels 3-4: Pretest vs. Posttest TD Patient Case for Treatment Pre (n=665) Post (n=550) 4. A 45-year-old male with a diagnosis of schizophrenia and stable psychiatric status has had dopamine receptor blocker induced tardive dyskinesia for 5 years. The treatment with the best combination of effectiveness and tolerability for treating persistent TD in this patient case is: A. Vitamin E B. Valbenazine or deutetrabenazine C. Omega-3 fatty acids D. Amantadine Understanding and the ability to evaluate a TD patient case for treatment suitability with valbenazine or deutetrabenazine increased by 53% following the educational activity. Given the new approvals of these agents, such clinical cases, and reinforced education surrounding them, are crucial for clinicians to identify, diagnose and select patients who would benefit from prescribing these new therapies and to utilize them accordingly % 62% 14% 1 14% 2% 2% 1%
19 Pretest vs. Posttest Response by Specialty 4. A 45-year-old male with a diagnosis of schizophrenia and stable psychiatric status has had dopamine receptor blocker induced tardive dyskinesia for 5 years. The treatment with the best combination of effectiveness and tolerability for treating persistent TD in this patient case is: Pre (n=228) Post (n=185) 98% 83% Pre (n=45) Post (n=37) 97% 78% Pre (n=391) Post (n=327) 94% 48% 9% 4% 1% 4% 1% 11% 4% 7% 3% 14% 18% 1% 3% 2% Psychiatrists Neurologists Other HCPs Understanding and the ability to evaluate a TD patient case for treatment suitability with valbenazine or deutetrabenazine increased modestly among psychiatrists and neurologists, yet robustly among general HCPs following the educational activity. Psychiatrists demonstrated an 18% increase, neurologists a 24% increase and other HCPs the highest level at 96%. Given the new approvals of these agents, such clinical cases and reinforced education surrounding them are crucial for clinicians to identify, diagnose and select patients who would benefit from prescribing these new therapies and to utilize them accordingly.
20 Activity Impact Self-reported activity impact Yes No No change Increase knowledge 65% 32% 3% Increase competence 54% 41% 5% Improve performance 51% 42% 7% Improve patient outcomes 49% 44% 7% 49% of attendees indicated participation in this activity will improve their patients outcomes. N=542; see comments on next slide
21 Activity Impact Self-reported increase in knowledge Able to recognize and understand tardive dyskinesia better Able to update my knowledge on newer evidence based pharmacological interventions for management of TD Awareness of newly available treatment options Better understanding of mechanisms of action Did not know what TD was, risk factors or treatment options as well as patient impact on QOL Extended knowledge in medical efforts Helped me know more about the two recently approved drugs Helped place in perspective differing treatments I am better to understand some of the affects related to TD when compared to psychiatric population and medication I have a better understanding of recognizing TD, risk factors and treatment with new agents Understanding of new class of medications that block packaging of neurotransmitter dopamine in the presynaptic nerve terminal The effective dosages of valbenazine and deutetrabenazine Learned more about 2 new agents and some off-label treatments I had no idea of the emerging treatments Although not a significant part of my practice, i find it incredibly interesting to learn Always great to learn about available medications Better at recognizing TD Collaborative team afford for better outcome for pts Did not know about new FDA approved meds (do not treat many schizophrenic pts) Familiarity with medications to treat TD is greater Gave evidence based information for future use of these meds Good review and extra knowledge I am a nurse so it help me understand and provide proper care and education to the patient I believe that after this activity I am better equipped to recognize, evaluate and treat patients who may unfortunately develop TD This was clinical information of which I was not associated. The entire CME was beneficial Provided information on recent results of clinical trials for the two new TD treatments It emphasizes affective disorders as higher risk for development of TD. I will start using TD med more readily
22 Activity Impact (Cont d) Self-reported increase in competence Aid in choosing alternative therapy for psychiatric treatment Awareness of treatment/evidence based outcomes Better able to assess diff movement disorders Better able to differentiate between TD and other conditions. Learned limitations of AIMS score Reinforced my practice of collaborating with neurologists and primary care providers to promote more effective outcomes I now have confidence in using these two new medications for my patients with tardive dyskinesia I now know to consider valibenazine or deutetrabenazine in patients who have tardive dyskinesia More competent in using antipsychotic meds in kids i see and in responding to td when it occurs Self-reported increase in performance Able to provider better patient education Be familiar with the ses and tx Better able to differentiate between moments of TD verses other movement disorders. Reinforced my practice of assessing TD in patients with history of dopamine receptor blocking agents and the need to add TD as a diagnosis requiring assessment during each clinic visit Help me be aware of TD in psychiatric patients I can possibly help patients with TD better than I used to be able to I feel better equipped to treat patients showing signs of TD, though it still makes me nervous when patients develop this unwanted SE Will screen the patient more carefully More likely to prescribe vmats Allow me to advocate for addition to our formulary Became aware of factors which increase the probability that a patient on dopamine blockers will develop TD Gave me more options to treat TD I can apply this to my clinical practice/pts. Via improved assessment and availability of drugs for TD I have a better understanding of recognizing TD, risk factors and treatment with new agents Importance of doing AIMS reassessment at intervals Increased confidence in using approved med's for TD More confident in the use of diagnostic criteria for tardive dyskinesia Will consider TD more profoundly in patients with abnormal movements; improve patient education prior to treatment Being aware of long term effects of dopamine antagonists if TD manifests Better awareness, earlier diagnosis Better understanding of new FDA drugs and efficacy shown through scientific trials. Concentrate on monitoring for emergent symptoms I am now more intuitive about the etiology and current treatment of TD I will be better to diagnose tardive dyskinesia and use the AIMS test to rate severity Proper combination of lowering the offending drug and adding a medicine to reduce TD Recognition of TD as separate from other movement disorders Screening and implementing appropriate measures
23 Activity Impact (Cont d) Self-reported increase in patient outcomes Anticipate higher level of satisfying outcome for pts Better symptoms control and functionality for pts Because I have been undermanaging this condition Better control of involuntary movements Earlier diagnosis, more effective treatment I currently have a patient with tardive dyskinesia that I plan to start on one of these medications I hope so- more awareness and treatment options are helpful I know the treatment and what dosing decreases sx Improved treatment for patients Reinforced my practice of the necessity to collaborate with other specialists a promote the best outcome for the TD patient More confidence use antipsychotics and manage td Patients will be more likely to remain on an antipsychotic that is benefiting them, now that the severity of TD can be greatly reduced This activity might improve my patient outcomes if I have patients with TD who respond well to valibenazine and deutetrabenazine Will be more sensitive to need for earlier DX and TX Appropriate referrals Better effectiveness and side effect burden Diagnosing TD and early management I commonly treat patient's with dopamine antagonists; therefore, my patients more susceptible to TD. I have a better understanding of recognizing TD, risk factors and treatment with new agents I will be more focused on recognizing even subtle TD and most important steps to take to reduce same or use the two new medications Increased my ability to diagnose TD and differentiate among other movement disorders Increased my understanding of recent clinical trials showing efficacy of the two new FDA approved therapies. Increased my knowledge about risk factors associated with TD, other than hx of dopamine receptor blocking agents. Validated my understanding of the limitations of the AIMS test for diagnostic purposes When I encounter patients on psychotropic meds, I will be more aware what to look for
24 Practice Change: Planned vs. Actual Since completing the activity, in what ways do you plan to change (or have changed) the management of your patients with tardive dyskinesia (TD)? Select all that apply Increase evaluation of my patients for the physical symptoms and/or manifestations of TD 54% 71% Increase referral of my patients suspected of having TD to a movement disorder specialist Greater utilization of FDA approved agents such as valbenazine and deutetrabenazine for treatment of patients with TD 32% 29% 37% Post (n=542) Follow-up (n=7) Other changes This activity validated my current practice; no changes will be made 4% 14% 17% 14% % of learners planned to change their practice immediately following the activity; in measuring the extent to which they implement through a follow-up survey of participants, 86% of respondents reported having changed their practice! Multiple responses allowed; see comments on next slide
25 Planned Practice Changes Self-attested changes to practice as a result of participating in this activity: Try to get approval for tx agents helpful for TD Identify suspicion of TD more consistently Initiate tx more readily Be more aware of TD symptoms Refer these patients to, or obtain in-hospital consultation of a specialist Attempt to get payment for meds More aware of new treatment available for TD Think of other differential diagnosis of TD Advice if seen implementing practical changes Aims testing more frequently. Re evaluate antipsychotics for MDD Assess medication list and neurological diseases Awareness of TD and prescribing options Be able to diagnose TD and refer to appropriate specialty Be more aware of meds that cause TD and observation of patients Better screen of movement disorder. Be on guard for TD on patients taking antipsychotics Careful evaluation plus neurological consulting Closer evaluation using AIMS Consider collaboration with neurologist Educate patient regarding new treatment option for TD Consider using these 2 drugs as opposed to amantadine or vitamin E Discuss with patients the risks and benefits of the newer medications for TD Spend more time on evaluation of abnormal movements to determine if they are due to tardive dyskinesia Inform patient of new treatment options if appropriate More closely watch for signs of TD in patients on dopamine receptor blockers Probably make early referrals to TD specialists Evaluation of tardive dyskinesia If positively td, then refer to the movement disorder specialist. Evaluate td 2. Differential diagnosis of TD Consider TD as a differential diagnosis. Be more vigilant evaluating movement disorders. Increase evaluation of my patients for TD Consider use of valibenazine and deutetrabenazine for patients with TD Consider the new FDA meds Promote this to colleagues Assess for TD and perform differential diagnosis Avoid excessive imaging studies, keep patients informed Be more alert to T.D. Symptoms. Be more aggressive in treating T.D. Spend more time in evaluating the condition and referring to correct help Implement usage of more medications with these potential because before I did not use these medications because of the hesitancy of creating TD. Now I have a better understanding of TD and what can be done if a patient develops this symptom Consider other movement disorders, prescribe these medicines Consider prescribing the two new drugs if covered by insurance Consider requesting from our pharmacy these TD approved medications - will require a non-formulary request Seek resources for patients who may not be able to afford the newer treatments Lower my threshold to prescribing the FDA approved agents for TD More complete history and physical exam to better make a recommendation for referral Perform AIMS test regularly, discuss benefit/risks of antipsychotic meds
26 Patient Care Impact Number of patients affected by these changes each month: >10 46% 11% 2% 2% 39% Changes will impact 1,389 to more than 2,711 TD patients each month. This assumes data in chart above is representative of all healthcare professionals that participated (2068), who indicated they have changed their practice as a result of their participation in this activity (86%). N=542
27 Barriers to Planned Change Cost Patient compliance issues 15% 16% Lack of time to assess/counsel patients 1 Lack of opportunity (patients) Lack of experience 23% 24% Reimbursement/insurance issues 18% Lack of administrative support 12% Lack of consensus or professional guidelines 4% Lack of resources (equipment) 8% Other 3% No barriers 18% 5% 1 15% 25% 3 Participants indicated lack of experience (24%) as most common barrier to implementing changes in their practice, followed by lack of opportunity (23%) and reimbursement/insurance issues (18%). Of those who identified barriers, 79% will attempt to address the perceived barrier(s) in order to affect change. N=542; multiple responses allowed
28 Level 5: Follow-up Survey Confidence How confident are you in utilizing an FDA approved agent such as valbenazine or deutetrabenazine for treatment of your patients with TD? Very confident 15% Follow-up Survey Moderately confident 57% Somewhat confident 14% Not at all confident 14% % of participants responded they were confident or very confident in using valbenazine or deutetrabenazine for treatment of TD patients. Future education that supports and enhances individualized education and reinforced real-world clinical applications would prove essential for maximal utilization in affected patients. N=7
29 Contact Information Richard Keenan VP, Education Development Academy for Continued Healthcare Learning (ACHL) E: P: ext. 215 C:
Advances in the Multidisciplinary Management of Hepatocellular Carcinoma: Strategies for Incorporating Emerging Immunotherapy Treatment Options
Advances in the Multidisciplinary Management of Hepatocellular Carcinoma: Strategies for Incorporating Emerging Immunotherapy Treatment Options Interim Outcomes Report Merck & Co., Inc. Grant ID: AAN-170919-044712
More informationTargeting the JAK/STAT Pathway in Immune-mediated Inflammatory Diseases: Current and Future Directions
Targeting the JAK/STAT Pathway in Immune-mediated Inflammatory Diseases: Current and Future Directions Interim Outcomes Report February 2019 Gilead Sciences, Inc. Grant ID: 02669 Overview Activity Description:
More informationFrom Psoriasis to Psoriatic Arthritis: Incorporating Advances to Individualize Treatment
From Psoriasis to Psoriatic Arthritis: Incorporating Advances to Individualize Treatment Final Enduring Outcomes Report Celgene Grant #20502 Janssen Grant #CE15843 Novartis Grant #NGC29612 Reflective of
More informationFINAL ENDURING OUTCOMES REPORT
FINAL ENDURING OUTCOMES REPORT OVERVIEW This report summarizes consolidated outcomes data from an enduring satellite symposium activity that was launched In March 2017 and ran for 12 months, cumulatively,
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Page 1 of 5 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Prime Therapeutics will review Prior Authorization requests Prior Authorization Form: https://www.bcbsks.com/customerservice/forms/pdf/priorauth-6514ks-ingr.pdf
More informationPrevention of HIV-related Cardiovascular Disease: an enewsletter Series
Prevention of HIV-related Cardiovascular Disease: an enewsletter Series Final Outcomes Report Gilead Grant ID: ZZ03-16 Data reflective through October 6, 2017 Series Landing Page Overview Activity: enewsletter
More informationFor Tardive Dyskinesia
A LOOK AT VMAT2 INHIBITORS DECEMBER 2017 For Tardive Dyskinesia Tardive dyskinesia (TD) is a repetitive, involuntary movement disorder caused by prolonged use of medications that block the dopamine receptor,
More informationACIP Recommendations for Adult Pneumococcal Immunization: Helping Pharmacists Assess, Recommend, Administer or Refer. Interim Outcomes Report
ACIP Recommendations for Adult Pneumococcal Immunization: Helping Pharmacists Assess, Recommend, Administer or Refer Grant ID: 29025501 Interim Outcomes Report https://www.powerpak.com/course/preamble/114079
More informationThe JAK/STAT Signaling Pathway and its Role in Immune-mediated Inflammatory Disease: Impact on the Treatment of RA
The JAK/STAT Signaling Pathway and its Role in Immune-mediated Inflammatory Disease: Impact on the Treatment of RA Final Outcomes Report Gilead Sciences ID: #02668 Series Overview The educational intervention
More informationArthritis: Incorporating
From Psoriasis to Psoriatic Arthritis: Incorporating Advances to Individualize Treatment Interim Outcomes Report Celgene Grant #20502 Janssen Grant #CE15843 Novartis Grant #NGC29612 Reflective of data
More informationVesicular Monoamine Transporter Type 2 Inhibitors: deutetrabenazine (Austedo ), tetrabenazine (Xenazine ), valbenazine (Ingrezza )
Vesicular Monoamine Transporter Type 2 Inhibitors: deutetrabenazine (Austedo ), tetrabenazine (Xenazine ), valbenazine (Ingrezza ) Applies to all products administered or underwritten by Blue Cross and
More informationComprehensive Strategies to Improve Clinical Outcomes in Heart Failure. Live and Enduring Interim Outcomes Report. Novartis Grant ID: NGC29501
Comprehensive Strategies to Improve Clinical Outcomes in Heart Failure Live and Enduring Interim Outcomes Report Novartis Grant ID: NGC29501 Program Information Overview This symposium and enduring material
More informationComprehensive Strategies to Improve Clinical Outcomes in Heart Failure. Live and Enduring Final Outcomes Report. Novartis Grant ID: NGC29501
Comprehensive Strategies to Improve Clinical Outcomes in Heart Failure Live and Enduring Final Outcomes Report Novartis Grant ID: NGC29501 Program Information Overview This symposium and enduring material
More informationFINAL OUTCOMES REPORT
OVERVIEW FINAL OUTCOMES REPORT The annual Endovascular Advances: A Hands On Preceptorship Program is a continuing medical education series designed to provide physicians with hands on training in all aspects
More informationMolina Healthcare of Texas
Texas Standard Prior Authorization Form Addendum Molina Healthcare of Texas Ingrezza (Marketplace) This fax machine is located in a secure location as required by HIPAA Regulations. Complete / Review information,
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 1Q18 January February
BRAND NAME Austedo TM GENERIC NAME Deutetrabenazine MANUFACTURER Teva Pharmaceuticals USA, Inc. DATE OF APPROVAL August 30, 2017 PRODUCT LAUNCH DATE Currently commercially available REVIEW TYPE Review
More informationParticipatory Medicine and Diabetes Care: A Clinician and Patient Education Initiative. Final Outcomes Assessment September 2017
Participatory Medicine and Diabetes Care: A Clinician and Patient Education Initiative Final Outcomes Assessment September 2017 Novo Nordisk Grant ID: 019262 CME Activity Page Patient Education Activity
More informationTargeting EGFR Mutationpositive
Targeting EGFR Mutationpositive NSCLC: Critical Advances in Care Interim Outcomes Report Data reflective through April 1, 2019 Pfizer Grant ID: 40809265 Overview Activity Description: A certified digital
More informationThe Emerging Science of Prophylactic Therapies for Migraine. Interim Outcomes Report. Lilly USA, LLC Grant ID: A 19557
The Emerging Science of Prophylactic Therapies for Migraine Interim Outcomes Report Lilly USA, LLC Grant ID: A 19557 Program Information Overview: This enduring webcast shares highlights from a live presentation,
More informationFINAL OUTCOMES REPORT
OVERVIEW FINAL OUTCOMES REPORT The annual Endovascular Advances: A Hands On Preceptorship Program is a continuing medical education series designed to provide physicians with hands on training in all aspects
More informationUS Tardive Dyskinesia Market: Size, Trends & Forecasts ( ) December 2016
US Tardive Dyskinesia Market: Size, Trends & Forecasts (2016-2025) December 2016 US Tardive Dyskinesia Market Report Scope of the Report The report entitled US Tardive Dyskinesia Market: Size, Trends &
More informationIngrezza (valbenazine)
Ingrezza (valbenazine) Policy Number: 5.01.635 Last Review: 7/2018 Origination: 07/2017 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Ingrezza
More informationClinical Updates for Nurse Practitioners and Physician Assistants: 2016
Clinical Updates for Nurse Practitioners and Physician Assistants: 2016 Avoiding the Pitfalls in IBD Care: Diagnostic and Management Strategies to Improve Outcomes Grant # IGRC 2016-028 Final Outcome Report
More informationOUTCOMES SUMMARY REPORT
Inhaled Corticosteroids in Asthma: The Balance Between Safety and Efficacy OUTCOMES SUMMARY REPORT Live Educational Activity Series May 5, 2016 December 15, 2016 ME201520772 Grant Number: 1950 MEDA Executive
More informationPresented at the American Psychiatric Association Annual Meeting May 20 24, 2017 San Diego, CA.
Original Presentations Key Words: amines, antipsychotic agents, double-blind method, mood disorders, psychopharmacology, psychotic disorders, schizophrenia, tardive dyskinesia, valbenazine Efficacy of
More informationDesigning an Electronic Medical Record-based Clinical Decision Support Tool to Improve CVD Screening in Rheumatoid Arthritis Patients
Designing an Electronic Medical Record-based Clinical Decision Support Tool to Improve CVD Screening in Rheumatoid Arthritis Patients Provided and Certified By Grant Award # 045604 Report Date: March 29,
More informationNew Jersey Department of Children and Families Policy Manual. Date: Chapter: A Health Services Subchapter: 1 Health Services
New Jersey Department of Children and Families Policy Manual Manual: CP&P Child Protection and Permanency Effective Volume: V Health Date: Chapter: A Health Services 1-11-2017 Subchapter: 1 Health Services
More informationXenazine. Xenazine (tetrabenazine) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Xenazine Page: 1 of 5 Last Review Date: November 30, 2018 Xenazine Description Xenazine (tetrabenazine)
More informationGetting With The Guideline: Managing Pediatric ADHD in Your. Primary Care Practice
Getting With The Guideline Managing Pediatric ADHD in Your Primary Care Practice Activity Evaluation Summary CME Activity: Course Director: Getting With The Guideline: Managing Pediatric ADHD in Your Primary
More informationPrior Authorization with Quantity Limit Program Summary
Gocovri (amantadine) Prior Authorization with Quantity Limit Program Summary This prior authorization applies to Commercial, NetResults A series, SourceRx and Health Insurance Marketplace formularies.
More informationCME/CE POSTTEST CME/CE QUESTIONS
CME/CE POSTTEST CME/CE QUESTIONS Controlling Asthma Severity: Identifying Unmet Needs and Optimizing Therapeutic Options There are no fees for participating in and receiving continuing medical education
More informationVesicular Monoamine Transporter 2 Inhibitors for Tardive Dyskinesia: Effectiveness and Value
Stakeholder Input Vesicular Monoamine Transporter 2 Inhibitors for Tardive Dyskinesia: Effectiveness and Value Revised Background and Scope June 9, 2017 This scoping document was developed with extensive
More informationAustedo. Austedo (deutetrabenazine) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.15 Subject: Austedo Page: 1 of 6 Last Review Date: September 15, 2017 Austedo Description Austedo
More informationHealthcare Implications of Achieving JNC 7 Blood Pressure Goals in Clinical Practice
CONTINUING EDUCATION Healthcare Implications of Achieving JNC 7 Blood Pressure Goals in Clinical Practice GOAL To provide participants with current information about current blood pressure goals and effective
More informationVesicular Monoamine Transporter 2 Inhibitors for Tardive Dyskinesia: Effectiveness and Value
Stakeholder Input Vesicular Monoamine Transporter 2 Inhibitors for Tardive Dyskinesia: Effectiveness and Value Draft Background and Scope May 8, 2017 This scoping document was developed with extensive
More informationOutcomes Summary. February 3-6, 2016 Keystone, Colorado
Outcomes Summary February 3-6, 2016 Keystone, Colorado Executive Summary Activity Details Background: The National Jewish Health Annual The Pulmonary and Allergy Update highlights insights and recent advances
More informationNew Mexico. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile New Mexico Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationPsychiatry for the Non-Psychiatrist. January 19, 2019
Psychiatry for the Non-Psychiatrist January 19, 2019 Overview A large percentage of patients visiting non-psychiatric practices suffer from psychiatric conditions alone or complicating medical, surgical
More informationRecommendations in Opioid Prescribing Guidelines for Chronic Pain
Recommendations in Opioid Prescribing Guidelines for Chronic Pain The use of opioids for treating chronic pain has been increasing. 1 In 2010, an estimated 20% of patients presenting to physician offices
More informationIngrezza. Ingrezza (valbenazine) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.29 Subject: Ingrezza Page: 1 of 5 Last Review Date: December 8, 2017 Ingrezza Description Ingrezza
More informationPROVIDED IN RESPONSE TO YOUR UNSOLICITED REQUEST FOR INFORMATION
KINECT 2 NCT01733121 Baseline Week 2 Week 4 Week 6 Valbenazine 25-75 mg Valbenazine 40 mg KINECT 3 NCT02274558 Valbenazine 80 mg a KINECT 2 and KINECT 3 were 6-week, double-blind placebo-controlled trials
More informationINTERQUAL BEHAVIORAL HEALTH CRITERIA ADOLESCENT PSYCHIATRY REVIEW PROCESS
INTERQUAL BEHAVIORAL HEALTH CRITERIA ADOLESCENT PSYCHIATRY REVIEW PROCESS RP-1 RP-2 AGE PARAMETERS Adolescent Psychiatry Behavioral Health Criteria are for the review of patients who are ages 13 to 17
More informationNot an actual patient
www.takeontd.com TD CAN BE A BURDEN ON PATIENTS AND AFFECT THEIR LIVES 1 TD can be disruptive, whether they have mild, moderate, or severe TD. 2 Patients with TD may deal with many issues Abnormal and
More informationNEUROLOGY & PSYCHIATRY FOR PRIMARY CARE. San Diego, California Hotel del Coronado December 8 10, 2017
NEUROLOGY & PSYCHIATRY FOR PRIMARY CARE San Diego, California Hotel del Coronado December 8 10, 2017 Friday, December 8th: 7:30 am 8:00 am Registration and Hot Breakfast 8:00 am 9:00 am Neurology The Neurological
More informationNEUROLOGY & PSYCHIATRY FOR PRIMARY CARE. Vail, Colorado Hotel Talisa February 9 11, 2018
NEUROLOGY & PSYCHIATRY FOR PRIMARY CARE Vail, Colorado Hotel Talisa February 9 11, 2018 Friday Morning, February 9th: 6:30 am 7:00 am Registration and Hot Breakfast 7:00 am 8:00 am Neurology 2 Evaluating
More informationHot Topics in. Thursday, October 5, Register Online! VindicoCME.com/ CASE CHOICE. Interactive Dinner Symposium 2.0.
Clinical Chief, /-certified Activity /-certified Activity This continuing Audience-driven, -based Learning Customized learning at your fingertips you choose case! Overview Agenda Antiretroviral rapy has
More informationNeurocrine Biosciences, Inc. THE NEUROENDROCRINE COMPANY
Neurocrine Biosciences, Inc. THE NEUROENDROCRINE COMPANY Safe Harbor Statement In addition to historical facts, these slides contain forward-looking statements that involve a number of risks and uncertainties.
More informationOklahoma. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Oklahoma Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationThe Challenges of Invasive Fungal Infections in Community Hospitals: A CME Guidebook to Improve Therapy and Clinical Outcomes
The Challenges of Invasive Fungal Infections in Community Hospitals: A CME Guidebook to Improve Therapy and Clinical Outcomes Interim Outcomes Report Astellas Grant ID: MED-5233634 Overview Activity Description:
More informationINTERQUAL BEHAVIORAL HEALTH CRITERIA GERIATRIC PSYCHIATRY REVIEW PROCESS
INTERQUAL BEHAVIORAL HEALTH CRITERIA GERIATRIC PSYCHIATRY REVIEW PROCESS RP-1 RP-2 AGE PARAMETERS Geriatric Psychiatry Behavioral Health Criteria are for the review of patients who are ages 65 and older.
More informationCME/CE QUIZ CME/CE QUESTIONS
CME/CE QUIZ CME/CE QUESTIONS Continuing Medical Education Accreditation The University of Cincinnati College of Medicine designates this educational activity for a maximum of two (2) AMA PRA Category 1
More informationUMASS TOBACCO TREATMENT SPECIALIST CORE TRAINING
UMASS TOBACCO TREATMENT SPECIALIST CORE TRAINING Course Description Goals and Learning Objectives 55 Lake Ave North, Worcester, MA 01655 www.umassmed.edu/tobacco 1 Table of Contents Determinants of Nicotine
More informationVesicular Monoamine Transporter 2 Inhibitors for Tardive Dyskinesia: Effectiveness and Value
Vesicular Monoamine Transporter 2 Inhibitors for Tardive Dyskinesia: Effectiveness and Value Final Evidence Report December 22, 2017 Prepared for Institute for Clinical and Economic Review, 2017 ICER Staff/Consultants
More informationFinal Outcomes Report 07/23/18
Final Outcomes Report 07/23/18 36880883 Personalized Medicine in Severe Asthma; Applying Emerging Data and Treatments to Everyday Clinical Practice Educational Objectives 1. Describe key concepts in the
More informationAdherence in A Schizophrenia:
Understanding and Diagnosing Bipolar Disorder Treatment Promoting for Bipolar Treatment Disorder Adherence in A Schizophrenia: Resource for Providers Engagement Strategies for Health Care Providers, Case
More informationSchizophrenia and Approaches to Recovery
Schizophrenia and Approaches to Recovery neurosciencecme Snack December 13, 2012 December 13, 2013 Supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific
More informationUCLA Sleep Medicine Course
Presents the 11th Annual UCLA Sleep Medicine Course Saturday, January 27, 2018 UCLA Campus, NRB Auditorium UCLA Sleep Medicine Course Introduction Physicians in all areas of medicine encounter patients
More informationImproving Asthma Care: An Update for Managed Care
n posttest n Improving Asthma Care: An Update for Managed Care Physician Continuing Medical Education Accreditation Statement This activity has been planned and implemented in accordance with the Essential
More informationNEURO/PSYCH FOR PRIMARY CARE. San Juan, Puerto Rico InterContinental San Juan February 25 28, 2016
NEURO/PSYCH FOR PRIMARY CARE San Juan, Puerto Rico InterContinental San Juan February 25 28, 2016 Thursday, February 25th: 7:30 am 8:00 am Registration and Hot Breakfast 8:00 am 9:00 am Neurology 1 The
More informationINTERNAL MEDICINE FOR PRIMARY CARE: GYNECOLOGY/MEN S UROLOGY/PAIN/PSYCHIATRY. London, United Kingdom The Savoy Hotel, London August 27 30, 2018
INTERNAL MEDICINE FOR PRIMARY CARE: GYNECOLOGY/MEN S UROLOGY/PAIN/PSYCHIATRY London, United Kingdom The Savoy Hotel, London August 27 30, 2018 Monday, August 27th: 7:00 am 7:30 am Registration and Arrival
More informationClinical Guidelines for the Pharmacologic Treatment of Schizophrenia
Clinical Guidelines for the Pharmacologic Treatment of Community Behavioral Health (CBH) is committed to working with our provider partners to continuously improve the quality of behavioral healthcare
More informationPharmacy Prior Authorization GMH/SA and Non-Title 19/21 SMI Non-Formulary and Prior Authorization Guidelines
Brand Name Medication Requests Non-Formulary Medications GMH/SA and Non- 19/21 SMI Mercy Care requires use of generic agents that are considered therapeutically equivalent by the FDA. For authorization
More informationPSYCHOTROPIC MEDICATION UTILIZATION PARAMETERS FOR CHILDREN AND YOUTH IN FOSTER CARE
PSYCHOTROPIC MEDICATION UTILIZATION PARAMETERS FOR CHILDREN AND YOUTH IN FOSTER CARE Introduction and General Principles April 2017 Adapted for New Mexico from with permission from the Texas Department
More informationAssessment and Diagnosis
Amaze Position Statement Assessment and Diagnosis Key points Autism assessment and diagnostic services should be available to all people who require them, irrespective of age, gender, locality, financial
More informationDESIGN TYPE AND LEVEL OF EVIDENCE: Randomized controlled trial, Level I
CRITICALLY APPRAISED PAPER (CAP) Hasan, A. A., Callaghan, P., & Lymn, J. S. (2015). Evaluation of the impact of a psychoeducational intervention for people diagnosed with schizophrenia and their primary
More informationPlease print clearly; illegible forms will delay your receiving credit/verification: City State ZIP. Yes No
PARTICIPANT INFORMATION Please print clearly; illegible forms will delay your receiving credit/verification: First Name MI Last Name Address 1 Address 2 City State ZIP Country Daytime Telephone Fax E-mail
More informationCould your uncontrollable movements be tardive dyskinesia (TD)?
Could your uncontrollable movements be tardive dyskinesia (TD)? For adults with TD, there's a convenient treatment with INGREZZA: One capsule, once daily. Important Information Approved Use INGREZZA (valbenazine)
More informationPsychotropic Medication. Including Role of Gradual Dose Reductions
Psychotropic Medication Including Role of Gradual Dose Reductions What are they? The phrase psychotropic drugs is a technical term for psychiatric medicines that alter chemical levels in the brain which
More informationSiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance]
SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA [compatible with NICE guidance] Medicines Management Committee August 2002 For review August 2003 Rationale The SiGMA algorithm
More informationSleep Disorders and Excessive Sleepiness: Impact on Quality of Life
CME/CE POSTTEST Sleep Disorders and Excessive Sleepiness: Impact on Quality of Life CME Information Program Overview Excessive sleepiness is a complaint found in patients who experience sleepiness at unwanted
More informationINTERNAL MEDICINE FOR PRIMARY CARE: ENDOCRINOLOGY/GASTROENTEROLOGY/INFECTIOUS DISEASE/ PSYCHIATRY
INTERNAL MEDICINE FOR PRIMARY CARE: ENDOCRINOLOGY/GASTROENTEROLOGY/INFECTIOUS DISEASE/ PSYCHIATRY Kapolei, Oahu, Hawaii Aulani, A Disney Resort & Spa June 24 28, 2018 Sunday, June 24th: 3:30 pm 4:00 pm
More informationPrimary Palliative Care Skills
Primary Palliative Care Skills Tools for Assessment and Management of Serious Illness for Primary Care Providers Comprehensive Curriculum Self-Paced Fully Online 03012018 Online, On-Demand Education for
More informationAddressing Today s Challenging Bacterial Infections: Expert Views on Treatment Paradigms
Addressing Today s Challenging Bacterial Infections: Expert Views on Treatment Paradigms Symposium Outcomes Report Merck Grant ID: AAN-180403-047752 Overview Activity Description: This symposium provided
More informationEssential Palliative Care Skills For Every Clinician
Essential Palliative Care Skills For Every Clinician Tools for Assessment and Management of Serious Illness for Primary Care Providers Comprehensive Curriculum Self-Paced Fully Online 03012018 Online,
More informationAUSTEDO (deutetrabenazine) oral tablet INGREZZA (valbenazine) oral capsule XENAZINE (tetrabenazine) oral tablet Tetrabenazine oral tablet
Tetrabenazine oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline
More informationJuly 7, Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
July 7, 2012 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA 2012-N-0408: Risk Evaluation and Mitigation Strategy Assessments:
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: No Coverage Criteria/Off-Label Use Policy Reference Number: CP.PMN.53 Effective Date: 07.01.18 Last Review Date: 05.01.18 Line of Business: Oregon Health Plan Revision Log See Important
More informationNEUROLOGY FOR PRIMARY CARE. San Diego, California Hotel del Coronado August 9 12, 2018
NEUROLOGY FOR PRIMARY CARE San Diego, California Hotel del Coronado August 9 12, 2018 Thursday, August 9th: 7:00 am 7:30 am Registration and Hot Breakfast 7:30 am 8:30 am Faculty 1 The Neurological Exam
More informationVesicular Monoamine Transporter 2 Inhibitors for Tardive Dyskinesia: Effectiveness and Value
Vesicular Monoamine Transporter 2 Inhibitors for Tardive Dyskinesia: Effectiveness and Value Evidence Report November 21, 2017 Prepared for Institute for Clinical and Economic Review, 2017 ICER Staff/Consultants
More informationCould your uncontrollable movements be tardive dyskinesia (TD)? There s a treatment with INGREZZA.
Lip smacking, eye blinking, dancing hands and fingers, hip jerking... Could your uncontrollable movements be tardive dyskinesia (TD)? There s a treatment with INGREZZA. Approved for adults with TD TD can
More informationA Coding System to Measure Elements of Shared Decision Making During Psychiatric Visits
Measuring Shared Decision Making -- 1 A Coding System to Measure Elements of Shared Decision Making During Psychiatric Visits Michelle P. Salyers, Ph.D. 1481 W. 10 th Street Indianapolis, IN 46202 mpsalyer@iupui.edu
More informationThe Emerging Science of Prophylactic Therapies for Migraine. Final Outcomes Report. Lilly USA, LLC Grant ID: A 19557
The Emerging Science of Prophylactic Therapies for Migraine Final Outcomes Report Lilly USA, LLC Grant ID: A 19557 Program Information Overview: This enduring webcast shared highlights from a live presentation,
More informationActivity Evaluation Summary
Activity Evaluation Summary CME Activity: Experts on Call: Current Issues in the Management of Osteoporosis, 2013-2014 Dates: December 2, 2013 December 17, 2013 January 27, 2014 Format: Course Director:
More informationINTERNAL MEDICINE FOR PRIMARY CARE: ORTHOPEDICS/PAIN MANAGEMENT/RHEUMATOLOGY/SPORTS MEDICINE
INTERNAL MEDICINE FOR PRIMARY CARE: ORTHOPEDICS/PAIN MANAGEMENT/RHEUMATOLOGY/SPORTS MEDICINE St. Maarten, Sint Maarten The Westin St. Maarten Dawn Beach Resort & Spa February 11 14, 2016 Thursday, February
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Rexulti) Reference Number: NE.PMN.68 Effective Date: 01/01/2017 Last Review Date: Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this
More informationRecommendations for Components of Emergency Department Discharge Protocols
Recommendations for Components of Emergency Department Discharge Protocols Background Maryland, like many other states, is in the midst of an opioid crisis. In 2016, 89 percent of all intoxication deaths
More informationUniversity of Kentucky Research Foundation, Managing Nicotine Withdrawal in Medical and Surgical Patients 3
D. Main Section of the proposal (not to exceed 10 pages) 1. Overall Aim & Objectives The goal of this project is to offer targeted training to health care providers about the management of tobacco dependence
More information2. Did the member receive this medication during a recent hospitalization? Y N
Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Antipsychotics (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationGeorgia Aging and Disability Resource Connection (ADRC) Evaluation Report
Georgia Aging and Disability Resource (ADRC) Evaluation Report Evaluation Report from Boston University March Prepared by: Bronwyn Keefe, MSW, MPH, PHD Associate Director, CADER Kathy Kuhn, MSW Director
More information2. Did the patient receive this medication during a recent hospitalization? Y N
Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Antipsychotics (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationThe South African Depression and Anxiety Group (SADAG) Competition Commission: Market Inquiry into the Private Healthcare Sector
The South African Depression and Anxiety Group (SADAG) Competition Commission: Market Inquiry into the Private Healthcare Sector Introduction SADAG is registered NGO since 1994 Leading Mental Health Advocacy
More informationNeed to brush up on your hospice and palliative medicine knowledge?
Need to brush up on your hospice and palliative medicine knowledge? LEARN FROM THE EXPERTS Enjoy the 2014 Intensive Board Review Course recordings (including synchronized PowerPoint presentations and MP3
More informationManaging Behavioural Problems in Patients with Learning Disabilities
Managing Behavioural Problems in Patients with Learning Disabilities Some people with a learning disability display behaviour that challenges. Although such behaviour is a challenge to services, family
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Policy Reference Number: CP.PMN.53 Effective Date: 09.12.17 Last Review Date: 11.18 Line of Business: Medicaid, HIM-Medical Benefit Revision Log See Important Reminder at the end of this
More informationTardive Dyskinesia New approaches in diagnosis and treatment
Tardive Dyskinesia New approaches in diagnosis and treatment Steven T. Szabo, MD, PhD Psychiatry and Behavioral Sciences Division of Translational Neuroscience Duke University Medical Center Durham, NC
More informationPolypharmacy and Deprescribing. A special report on views from the PrescQIPP landscape review
Polypharmacy and Deprescribing A special report on views from the PrescQIPP landscape review Introduction and background In recent years, we have seen the emergence of an international discussion around
More informationPEDIATRIC & ADOLESCENT MEDICINE FOR PRIMARY CARE: GASTROENTEROLOGY/GYNECOLOGY/PSYCHIATRY/ RHEUMATOLOGY
PEDIATRIC & ADOLESCENT MEDICINE FOR PRIMARY CARE: GASTROENTEROLOGY/GYNECOLOGY/PSYCHIATRY/ RHEUMATOLOGY San Juan, Puerto Rico The Ritz-Carlton, San Juan March 15 18, 2018 Thursday, March 15th: 7:30 am 8:00
More information